What Is Supplementary Protection Certificate?
A Supplementary Protection Certificate (SPC) is an IP right that extends patent protection for pharmaceutical and plant protection products by up to five years, compensating for the time lost during mandatory regulatory approval processes before the product can be marketed.
SPCs exist because pharmaceutical and agrochemical products face a unique disadvantage in the patent system. While patents last 20 years from filing, these products cannot be sold until they receive regulatory approval (such as marketing authorisation from the EMA, MHRA, or FDA). This approval process can take 10-15 years, leaving only a few years of effective patent protection to recoup R&D investment. An SPC effectively extends the patent term by the period between the patent filing date and the date of first marketing authorisation, minus five years, up to a maximum of five additional years. In the EU, a paediatric extension can add six months beyond that. The SPC covers only the specific product approved by the regulatory authority, not all uses of the patented compound. SPCs are available in the EU (under Regulation EC 469/2009 for medicinal products and EC 1610/96 for plant protection products) and the UK (post-Brexit). The US has an equivalent mechanism through Patent Term Extension under the Hatch-Waxman Act (35 U.S.C. 156). Other jurisdictions have similar provisions, though the details vary.
Why It Matters
SPCs are critically important for the pharmaceutical industry because drug development costs billions of pounds and regulatory approval consumes a large portion of the patent term. Without SPCs, innovators would have insufficient time to recover their investment before generic competition enters. SPCs balance the need for innovation incentives with eventual generic access, directly affecting drug pricing and availability.
How This Connects to IP Protection
immut supports the SPC process by providing timestamped evidence of key development milestones. Since SPC calculations depend on precise dates — patent filing, regulatory submissions, and marketing authorisations — having blockchain-verified records of the R&D timeline strengthens applications and helps resolve disputes over the correct SPC duration.
Common Mistakes to Avoid
SPCs extend the full patent for five years: An SPC only extends protection for the specific approved product, not the entire scope of the original patent. If a patent covers multiple compounds but only one received marketing authorisation, the SPC applies only to that one product.
SPCs are available for all patented products: SPCs are limited to pharmaceuticals and plant protection products — sectors where regulatory approval significantly delays market entry. Other industries, even those with lengthy development timelines, do not benefit from SPC extensions.
SPCs always grant five extra years: Five years is the maximum. The actual extension is calculated as the time between patent filing and first marketing authorisation, minus five years. If regulatory approval was obtained relatively quickly, the SPC duration will be shorter — and it can be zero if the approval took less than five years after filing.
Frequently Asked Questions
How is the duration of an SPC calculated?
The SPC duration equals the time between the patent filing date and the date of first EU/UK marketing authorisation, minus five years. The maximum is five years (plus six months if a paediatric extension applies). For example, if a patent was filed in 2010 and marketing authorisation granted in 2022, the SPC would be 12 minus 5 = 7 years, capped at 5 years.
Can a generic company challenge an SPC?
Yes. Generic manufacturers can challenge SPCs on validity grounds, including arguing that the basic patent did not protect the product, that the marketing authorisation was not the first for the product, or that the SPC was incorrectly calculated. SPC litigation is common and can significantly affect generic entry dates.
Do SPCs exist outside Europe?
Yes, though under different names. The US has Patent Term Extension under the Hatch-Waxman Act. Japan, Australia, South Korea, and several other countries have equivalent mechanisms. The specific rules, calculations, and maximum extensions vary by jurisdiction.
Protect Your Intellectual Property Today
Whether you are navigating supplementary protection certificate or building a broader IP strategy, immut gives you instant blockchain-verified proof of your innovations — no lawyers, no delays.